MAIA · MAIA Biotechnology, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on MAIA. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About MAIA · MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Live Quote
HOLD (score -2) · 12-1 mom -26.4% · RSI 53.7 · above_50_only · -53.2% from high
Targets blend Wall Street consensus (2 analysts: low $10.27 / mean $12.13 / high $14.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
Stage crashed before producing an artifact (e.g. LM Studio timeout, malformed JSON, network error). The cooldown will hold this off the queue for ~1h before retry.
MAIA is a clinical-stage oncology biotech with one lead asset — Ateganosine (THIO) — in Phase 3 for NSCLC. The investigation trigger was met: CEO Vlad Vitoc purchased $100,880 on June 1, Chief Scientific Officer bought $2,690 that same day, and Director Stan Smith bought ~$100,200 that same day; these are verified open-market P-code transactions within the last 14 days. Phase 3 trial (THIO-104) presented at ASCO 2026 with FDA Fast Track designation granted. Cash position strengthened by $33M capital raise in March-April. The stock has collapsed from a January 2026 high of ~$3.19 to ~$1.30 (~59% drawdown), creating a valuation disconnect vs. late-stage clinical momentum. No options market exists (illiquid micro-cap). The smart-money cluster is genuine and the catalyst list is strong, but the lack of revenue, negative FCF, and single-asset risk are severe anti-signals that limit conventional structure selection.